Drug intelligence / Profile preview

HPV16-E7-T512

Development stage: Phase 1
Lead developer: Gilead Sciences
Modality: Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies

Overview

HPV16-E7-T512 is a transcription activator-like effector nucleases (TALEN)-edited plasmid designed to target the E7 epitope of human papillomavirus type 16 (HPV16). This gene-editing approach aims to disrupt or modify the viral E7 oncogene, which plays a critical role in the development and maintenance of HPV-associated malignancies. By targeting and editing this specific viral sequence, T512 may inhibit tumor growth or promote immune-mediated clearance of infected cells. The therapy represents an investigational gene-editing strategy for treating cancers associated with high-risk HPV infection[1].

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on HPV16-E7-T512.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPV16-E7-T512.

Explore the full profile